Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
about
Panoramic ultrasound: a novel and valid tool for monitoring change in muscle massNegative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal CancerPrognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients.Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladderLoss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients.Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling PathwaysChemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.Sarcopenia and chemotherapy-mediated toxicityLow skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer.Cachexia: clinical features when inflammation drives malnutrition.Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients.Impact of sarcopenia in the management of urological cancer patients.Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials.The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.Reply to L.E. Daly et al.Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer.Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer".Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer.Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer.Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.Fenofibrate prevents skeletal muscle loss in mice with lung cancer.Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.Lung Cancer Cachexia: Can Molecular Understanding Guide Clinical Management?Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
P2860
Q33813569-2A1A1A5C-5AE4-45A0-B979-25924376132FQ35662253-68705BA5-63F3-4709-94C6-AF1EBC88E6B8Q36255549-6BEA46F9-6DF9-45FC-99CB-1E7169F84408Q36328773-5FADF592-ABD2-4485-9C27-7724A9D74966Q36662147-388781A9-9EA8-4E1F-947F-52520B2CF294Q37350003-4B53CD14-3D66-4C71-A7CF-1040F2F54043Q37536603-89D0DD25-6244-4235-A87B-FD0B0AD03EEBQ37572738-3543D69C-7CCB-4615-8C4A-69637B0DFF70Q37734752-ECBF70B3-1CC9-4BE1-82AE-C2694BB1B7A1Q38391442-C2212A6D-12CD-4BB5-A9AA-0A9274B996A6Q38633201-5A2EDE7A-AEE4-45EA-8FFC-2E019904BFE3Q38749004-DCDAC6FE-C189-4AB3-BAFA-83EB478A3B31Q38821210-C0556F15-C31B-4068-84E0-70B5755A647CQ38842194-278094F2-9254-46C1-A427-85CD3E3B4DECQ40387345-4149556C-A47E-44E6-8806-571C75E3FF0EQ41086711-01736E4D-ED6E-43C0-902E-C8465A39DD08Q41485323-7EBA20E6-FB33-4DBD-820D-64BF8F69BE55Q41541734-C798FD62-BF07-42B6-BDFF-3A7B33F001B4Q42052388-D345A9C0-B419-40B0-BAE6-4AA4E9A6C278Q42336238-B4C4AD58-B61E-4725-8748-75F541497A64Q47260860-F0D60C14-ADC4-4EFB-B55B-715EA9ECAC9FQ47418565-104E3D00-2BD0-4C8C-AB39-5C0FFD03ED9BQ47736389-1291AC8B-8357-4B4F-B789-FE1B73561B3EQ47801764-19789333-C8E7-4368-A0EB-085938E566A7Q48309385-82D9C040-0CDB-4BC9-896D-3AE04C20B130Q48546803-13EA9D19-1FB6-4340-AB96-59B7509567A7Q49937482-7606D977-0066-4E7E-BAF9-D6B8A597EEACQ50109104-57285370-6637-4C4D-85EF-664137EA357FQ50126290-00E27D80-0D1B-451E-9C69-9DC6DDB3C4A9Q55196969-22B4ABD5-ED10-49DE-A55B-52B6FC52EC26Q57164295-CEB156BA-8B90-44BC-AD78-DF3B10C7C36DQ58705089-6AECAD3F-64A5-415D-9C27-8E245A22B680
P2860
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@en
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@nl
type
label
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@en
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@nl
prefLabel
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@en
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@nl
P2093
P2860
P1433
P1476
Changes in skeletal muscle mas ...... nts with advanced lung cancer.
@en
P2093
Bjørn H Grønberg
Guro B Stene
Harald Hjelde
Jorunn L Helbostad
Sveinung Sørhaug
Tore Amundsen
P2860
P304
P356
10.3109/0284186X.2014.953259
P50
P577
2014-09-16T00:00:00Z